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population. In addition, no essay attempts to define the elderly. Are clients in their 60s
similar toothers in their 80s and 90s? One is left with little regard for the lifecycle as a
viable force past adulthood. Several ofthe cases presented raise interesting issues but,
again, do not place them within a meaningful context. One exception in Part II is an
essay by Lawrence Breslau on the Exaggerated Helplessness Syndrome. This syn-
drome, in which elderly patients become maladjusted to their disabilities, highlights
their passivity and serves to maintain the support of primary caregivers. The
psychodynamic issues here are ripe for intervention, and Breslau provides good clinical
examples.
Part III, entitled "Specific Psychotherapeutic Modalities," picks up many issues
from Part I and ends with a real gem: an essay entitled "The Whole Grandfather: An
Intergenerational Approach to Family Therapy" by Etta Ginsberg McEwan. The
other essays focus on crisis management and short-term and group geriatric psycho-
therapy, and the information provided here is perhaps the most practical for readers,
since it addresses the appropriate structure of therapeutic intervention. For example,
Kahana's chapter on crisis management presents a crucial skill for the intakeofelderly
clients. He provides a working definition for geriatric crisis, along with many useful
clinical pieces. Ginsberg McEwan's essay, coming second to last, is poignant and infor-
mative, presenting an entire case study within the context of family and inter-
generational therapy. It speaks to the very intent of the book in tying together the
therapeutic goals of the elderly with those of children and grandchildren. By juxta-
posing these issues, Ginsberg McEwan illustrates points ofcommon interest as well as
age-specific ones.
Sadavoy and Leszcz's collection ofessays will, it is hoped, serve to encourage study
along the lines of its distinguished contributors. Although several essays are a bit
incongruous with the book's focus on treating the elderly, one should not be dis-
couraged. There has simply not been enough longitudinal work on the elderly, and the
very concept, both before and after reading the book, remains a diffuse notion of
"people 65 years and older." What emerges from the book, then, is not a specific
definition, but a well-rounded appreciation for the complex issues facing the elderly
and the enormous potential for therapeutic intervention.
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Important Advances in Oncology 1988 is the fourth annual volume in a series
dedicated to the review of significant and timely advances in oncologic research and
practice. Similar to previous volumes, the book comprises 15 chapters written by 34
authors and is divided evenly between basic research and clinical progress. This year's
edition even exceeds the previously reviewed 1987 volume in its remarkably consistent
presentation of well-written and thoroughly referenced review articles by leaders in
each selected field.
For the second year in a row, the editors have chosen the phenomenon ofmulti-drug
resistance (MDR) as one of the basic science subjects reviewed. MDR, currently ofBOOK REVIEWS
considerable interest in the cancer research community, is defined as the ability of
cancer cells to develop a broad cross-resistance to a number of structurally diverse
chemotherapeutic agents after exposure to a single drug such as doxorubicin or
vinblastine. Since last year's edition of this book, in which the biochemistry of MDR
was discussed, remarkably rapid advances have occurred in the elucidation of the
molecular biology ofthis form ofdrug resistance, providing ample material for further
review. Drs. Pastan and Gottesman ofthe National Cancer Institute aptly describe the
cloning of the mdr 1 gene, which is amplified or overexpressed in many mammalian
MDR cell lines, and the ability of an mdr 1 cDNA expression vector to confer the
MDR phenotype on drug-sensitive cells upon transfection. The mdr 1 gene product
appears to be P-glycoprotein, a high-molecular weight membrane-spanning protein
with sequence homology to bacterial transport proteins. It appears to function as an
energy-dependent drug pump to transport chemotherapeutic drugs out of cancer cells.
It also pumps natural toxins out ofcertain normal tissue cells which have been found to
express the mdr I gene. While increased understanding of the molecular biology of
MDR has yet to be translated into the clinic, the discovery that clinically used agents
such as verapamil and phenothiazines can function as "chemosensitizers" to reverse
P-glycoprotein-mediated resistance, possibly by competing for chemotherapeutic drug
binding sites, holds future promise for combination therapy and has already resulted in
the initiation of several clinical trials.
Another biochemical mechanism by which tumor cells may become resistant to a
variety of drugs is through alterations in DNA topoisomerases. Warren Ross is the
principal author of an excellent and thorough review of the action of topoisomerase I
and II, enzymes which cleave one or both strands ofDNA to allow relaxation necessary
for events such as replication. One ofthe most intriguing and only recently understood
aspects of the topoisomerases is that they serve as a drug target for intercalating
chemotherapeutic agents such as doxorubicin, m-AMSA, ellipticene congeners, and
epipodophyllotoxins, resulting in protein-associated DNA strand breaks, termed
"cleavable complexes." The unique consequence in cancer chemotherapy ofan enzyme
which is an active effector of drug action is that diminished levels or activity of this
enzyme will result in drug resistance. In fact, cell lines resistant to intercalating agents
have been developed by Ross and colleagues. These cells appear to have structurally
altered topoisomerases, revealing important aspects of both topoisomerase-mediated
cytotoxicity and drug mechanism of action. Dr. Ross concludes this review by raising
questions as to why cleavable complex formation is lethal to cells and discussing the
unique opportunity for pharmacologic intervention with novel, isozyme-specific antag-
onists oftopoisomerases.
The remaining five chapters, which comprise the basic science contributions to this
book, describe recent advances in molecular genetics and the characterization of var-
ious growth factors. "Recessive" oncogenes, genes which are involved in tumorigenesis
only upon their homozygous inactivation, are discussed with regard to retinoblastoma,
Wilm's tumor, rhabdomyosarcoma, and other dominantly inherited solid tumors.
Quantitative abnormalities in the expression of several proto-oncogenes are related to
clinical prognosis, providing some of the first apparent clinical applications of the
enormous advances made in the understanding of oncogenes and their products.
Malcolm Moore reviews the in vitro and in vivo activities of the rapidly growing
number ofhematopoietic growth factors involved in bone marrow stimulation. Finally,
John Minna and colleagues describe the identification of specific autocrine growth
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factors produced by human small cell lung cancer cell lines; these factors include the
bombesin-like gastrin-releasing peptide. They also discuss thedevelopment ofantibod-
ies to these growth factors, leading to clinical trials with antipeptide hormone
antibodies in humans.
The second half of the volume is concerned with clinical advances and issues in
oncology. Steve Rosenberg reports in detail the accumulated results of his well-
publicized phase II trials of IL-2 alone and IL-2 with LAK cells in patients with
metastatic cancer. A modest number ofresponses were seen, especially in patients with
renal cell cancer and melanoma, suggesting that adoptive immunotherapy, though
wrought with numerous side effects, may hold some promise of efficacy. Future gains
are discussed with regard to the combination of standard chemotherapeutic drugs or
tumor-directed monoclonal antibodies with LAKcells plus IL-2, as well as the recently
discovered tumor-infiltrating lymphocytes (TILs), which display more specific and
potent antitumor activity. Also noteworthy is an excellent review of the biology,
clinical understanding, and current therapeutic options for treating CML, including
bone marrow transplant and interferon.
As a whole, this book accurately portrays the current state of oncology, character-
ized by many exciting advances in the laboratory, but few frank successes in the clinic.
Many ofthe basic science fields reviewed in this volume, however, appear to be moving
quickly toward an era of clinical relevance and expansion, and it is to be hoped that
some of the novel strategies to combat cancer discussed in the basic science chapters
will appear in theclinical chapters in future editions ofthis series. Important Advances
in Oncology 1988 is an excellent source ofvery readable reviews in experimental can-
cer biology and treatment and continues to be a good resource both for clinicians and
researchers involved in oncology or pharmacology, as well as for students interested in
the molecular biology and pharmacology ofcancer.
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As the title states, Visual Histology is an atlas of microanatomy. While one may
argue that there is little need at this time for another histology atlas in a field that
already contains several excellent texts, I feel that this atlas warrants serious
consideration.
Like all of the other histology atlases, the text is a collection of pictures of various
tissue sections. The book is subdivided into 20 chapters, with sections on cells and their
organelles, tissue types, and the major organs of the body. Each of the illustrations
occupies an entire page and depicts details that are frequently difficult to discern in the
smaller pictures ofother atlases. The micrographs beautifully illustrate the structures
and characteristics of the cells and tissues in question. Moreover, a one-page vignette
accompanying each plate gives insights into the structure-function relationships ofthe
described cell, tissue, or organ. As a final useful item, the authors have italicized
various key terms as these are encountered for the first time and have compiled these
terms into a workable glossary.